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Abstract Substance P (SP) has been reported to induce 
inflammatory cytokine production in human neuroglial cells 
and peripheral lymphoid cells as well. In order to evaluate the 
potency of novel non-peptide antagonists of the tachykinin 
receptors as inhibitors of SP-induced cytokines, we used the 
astrocytoma cell line U373MG and blood mononuclear cells as 
models of central and peripheral SP-target cells, respectively. In 
tlk. first part of this study, we showed that SR 140333, an NKI 
tachykinin receptor antagonist, was able to inhibit strongly the 
SP-indoced production of interleukin (IL)-6 and IL-8 in the 
astrocytoma cell line. The antagonistic activity of SR 140333 
toward SP-induced cytokine production was specific and could 
not be attributed to a general anti-cytokine ffect, since cytokine 
release induced by another inflammatory protein such as IL-I~ 
was not blocked by this compound. In addition, NK2 and NK3 
agonist neuropeptides were at least 1000-fold less effective than 
SP, while SR 48968 and SR 142801 which are selective NK2 and 
NK3 receptor antagonists, respectively, displayed a 2.5-3 orders 
of magnitude lower inhibitory potency than SR 140333. All these 
data indicated that SR 140333 blocked SP-induced cytokine 
production in U373MG astrocytic cells via a specific NKI 
receptor-mediated process. Since SP has also been described to 
trigger peripheral blood mononuclear cells (PBMNC) or 
monocytes to release inflammatory cytokines, we attempted, in 
the second part of this study, to evaluate the potential 
antagonistic effect of our compounds on these cells. Experiments 
oil human PBMNC from different donors were carried out to 
determine first their pattern of cytokine production upon SP 
stimulation. Surprisingly, we noticed that SP at concentrations 
ranging from 0.I to I000 nM was unable to stimulate the release 
of any inflammatory cytokine tested. This raises the question of 
the specificity of the reported in vitro effects of SP on cytokine 
production by human peripheral immune cells. 
A~y words: Substance P; Tachykinin receptor antagonist; 
C ctokine; Astrocyte; Monocyte: Mononuclear cell 
in humans by stimulating cytokine production in the brain. 
Indeed, functional SP receptors have been identified in mouse, 
rat and human astrocytes [24] and these cells play important 
auxiliary roles in immune and inflammatory responses in the 
central nervous ystem (CNS). They act as antigen-presenting 
cells and produce cytokines uch as interleukin (IL)-I[~, IL-6, 
tumor necrosis factor (TNF)-c~, in response to inflammatory 
mediators [5]. Thus, SP-stimulated production of inflamma- 
tory cytokines by astrocytes could exacerbate inflammatory 
processes in the CNS and be involved in different neuro- 
pathologies. In this regard, the discovery of a high density 
of SP-immunoreactive astrocytes in multiple sclerosis plaques 
[6] is of particular importance. 
Using the U373MG cell line which expresses high levels of 
glial acidic fibrillary protein and functional SP receptors [7], 
as a model of human astrocytes, we sought to evaluate 
whether the novel non-peptide NK1 receptor antagonist SR 
140333 [8] was able to interfere with SP-triggered inflamma- 
tory cytokines in human astrocytes. For comparison, we have 
also studied the effects of SR 48968 and SR 142801 which are 
selective NK2 and NK3 receptor antagonists, respectively 
[9,10]. 
In addition to being a potent inducer of proinflammatory 
cytokines in the CNS, SP has also been reported to act at the 
periphery by stimulating the production of these mediators in 
human peripheral blood mononuclear cells (PBMNC) [11 13]. 
With regard to the importance that this peripheral influence 
could have in chronic inflammatory diseases and the beneficial 
effects that specific SP antagonists could represent, in the sec- 
ond part of this study we evaluated the impact of SP on the 
secretion of several 'acute-phase' proinflammatory c tokines 
from peripheral mononuclear cells of different donors. 
2. Materials and methods 
I Introduction 
Substance P (SP) is a neurotransmitter, member of the ta- 
ct~ykinin family of neuropeptides. These peptides released 
fi 3m primary sensory nerves exert their actions through acti- 
v ttion of G-protein coupled receptors, denoted neurokinin 1 
(NK1), NK2, NK3 and having preferential affinity for SP, 
n~:urokinin A (NKA) and neurokinin B (NKB) respectively 
[1]. In addition to being a key mediator of pain, SP may 
c, mtribute to the pathophysiology of neuronal inflammation 
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2.1. Peptides. cytokines and SR compounds 
SP, NKA, NKB, were purchased t¥om Bachem (Voisins-le-Breton- 
neux, France). Stock solutions of peptides (2 mM) were stored as 
frozen aliquots in pyrogen-free water. Recombinant human IL-113 
was obtained from Genzyme (Paris, France). SR 140333, SR 48968 
and SR 142801 [8-10] were synthesized at Sanofi Recherche (Mont- 
pellier, France) and stock solutions (2 mM in ethanol) were stored at 
-20°C. SR compounds were diluted to the appropriate concentra- 
tions in culture medium. The proportion of ethanol in culture media 
did not exceed 0.01% (v/v), which was shown to have no effect on 
cytokine induction. 
2.2. Cell preparations and cultures 
The human astrocytoma cells U373MG were obtained from the 
American Type Culture Collection (Rockville, MD, USA). They 
were grown in Dulbecco's modified Eagle's culture medium supple- 
All rights reserved. 
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mented with 10% fetal bovine serum (FBS), penicillin (50 U/ml) and 
streptomycin (50 btg/ml). PBMNC were isolated from heparinized 
blood, obtained from healthy donors, by centrifugation ver Ficoll 
Paque (Pharmacia Biotech, Uppsala, Sweden). For cytokine induc- 
tion, U373MG cells were plated in sextuplicate at 0.5-1 × 105/well in 
96-well microplates and incubated overnight in medium with 1% FBS. 
Cells were then washed twice with serum-free medium and treated in a 
total volume of 200 pl with the various timuli n 1% FBS culture 
medium containing 15 p.g/ml of the endotoxin inhibitor polymyxin B
sulfate (Sigma, Saint Quentin Fallavier, France) for an additional 18 
24 h. PBMNC were identically treated except for the overnight pre- 
incubation and for the presence of polymyxin when LPS (E. coli 
055:B5, Sigma) was used as stimulus. Cell-free supernatant samples 
were stored at -20°C prior to cytokine assays. 
2.3. Cytokine assays 
IL-II3, IL-6, IL-8, and TNFc~, were measured using ELISA kits 
(R&D Systems, Abingdon, UK) according to the manufacturer's spe- 
cifications. Data were expressed as mean + S.D. of triplicate assays 
performed with supernatants collected and pooled from six wells. 
Unless otherwise stated, each experiment was performed at least 
twice. 
3. Results 
production by these cells is not mediated by undetectable 
amount of IL-1 [14]. 
Astrocytes are, however, sensitive to stimulation by IL-118, a 
cytokine which could also play a role in some neurologic 
diseases as an inducer of inflammatory cytokines [5]. We 
therefore valuated the impact of a cotreatment with both 
SP and IL-113. As shown in Fig. 2, IL-113 alone increased 
IL-6 secretion in a concentration-dependent manner. What 
we showed in this study is that the presence of 100 nM SP 
potentiated the effect of IL-118 at all concentrations tested. 
The addition of 1 ~tM SR 140333 to the cells cotreated with 
IL-118 and SP allowed suppression of the enhancing effect of 
SP without affecting the stimulating effect of IL-118. Indeed, 
SR140333 reduced IL-6 levels in cultures costimulated with 
both stimulating agents to those observed with IL-113 alone. 
This clearly indicated that SR 140333 specifically blocked cy- 
tokine production induced by SP without interfering with an- 
other stimulus. The SP-receptor specificity of cytokine inhibi- 
tion by SR 140333 was further strengthened by comparative 
studies with specific NK2 and NK3 agonists and antagonists. 
3.1. SR 140333 blocks SP-induced inflammatory cytokines in 
human astrocytes 
In accordance with previous data [7], SP induces in U373 
MG astrocytoma cells a concentration-dependent release of 
IL-6 with an ECs0 of 3 nM (Fig. 1A). In addition, we showed 
for the first time that SP was also able to stimulate IL-8 
secretion by these cells within the same range of concentra- 
tions (Fig. 1B). In the presence of SR 140333, production of 
both IL-6 and IL-8 induced by 10 nM SP was maximally 
inhibited for concentrations of antagonist ranging from 10 -7 
to 10 -6 M and IC~0 was evaluated inboth cases at about 2 nM 
(Fig. IC,D). SR 140333 alone did not affect cytokine 
release (not shown). The inflammatory cytokines IL-1 and 
TNFa were not detected in the supernatants of SP-stimulated 
U373MG cells and it is noteworthy that SP-induced cytokine 
3.2. SR 140333 inhibits cytokine production via a specific NK1 
receptor-mediated process 
Extensive binding studies in different models [8,15,16] have 
demonstrated that SR 140333 is a highly selective NK1 recep- 
tor antagonist. On a functional basis, the experiments de- 
picted in Fig. 3 confirmed that profile in the model of cytokine 
induction in astrocytoma cells. First, the NKI agonist SP was 
compared to NKA and NKB which are selective agonist neu- 
ropeptides of NK2 and NK3 receptors, respectively. Fig. 3A 
shows that SP was 3-3.5 orders of magnitude more potent 
than either NKA or NKB as an IL-6 inducer. Second, SR 
140333 was compared to SR 48968 and SR 142801 which are 
selective and potent antagonists of NK2 and NK3 respectively 
[9,10]. As shown in Fig. 3B, IL-6 inhibition by SR 140333 was 
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Fig. 1. Effects of SP and SR 140333 on IL-6 and IL-8 production by U373MG cells. Cells were incubated as mentioned in Section 2 with the 
indicated concentrations of SP (A,B) or simultaneously treated with 10 nM SP and the indicated concentrations of SR 140333 (C,D). 
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wit h either NK2 or NK3 receptor antagonists. These results 
stnmgly argued for a selective involvement of NK1 receptors 
in cytokine induction from SP-stimulated U373 MG astrocy- 
toma cells. 
3.5 Effect of SP on cytokine release by human PBMNC 
",;P has been reported to induce at the periphery, on human 
m~ nocytes or mononuclear cells in general, an effect similar to 
th~:t described above on astrocytes [11-13]. In order to eval- 
uae  our different neurokinin antagonists on these peripheral 
ta~ get cells, we first evaluated the impact of SP on different 
inI'iammatory cytokines produced by human PBMNC. A typ- 
ic~.~[ experiment is depicted in Fig. 4 where 1L-113, IL-6 and 
TNF~ were measured. Whereas LPS (100 ng/ml), a well- 
known inflammatory cytokine inducer, triggered PBMNC to 
rel ease the three cytokines, no significant effect of SP, at con- 
ce Jtrations ranging from 10 -1° to 10 -6 M, was in any case 
observed above basal evel. Furthermore, the peripheral blood 
cels of three other donors identically treated demonstrated 
th,: same high sensitivity to LPS and the same absence of 
re.ponse to SP (not shown). 
~,ince direct treatment of PBMNC with SP had no effect, we 
ne~t studied its potential effect on cells costimulated with 
coacentrations of LPS ranging from 0.1 to 100 ng/ml. As 
shown in Fig. 5, LPS alone, as expected, induced a concen- 
tn,tion-dependent i crease in IL-6 release by human PBMNC. 
C, btreatment with 1 pM SP was devoid of any effect even at 
th,~" lowest suboptimal concentrations of LPS. 
4. Discussio• 
In this study we clearly showed that SR 140333 potently 
a]~d selectively inhibited the inflammatory cytokines IL-6 and 
II -8 induced by SP-stimulation of the NK1 receptor in the 
h~man astrocytoma cell line U373MG. In the CNS, the in- 
d~Lction of inflammatory cytokines by SP-stimulated astro- 
c x tes may be involved in the pathophysiology of inflammatory 
m:urodegenerative disorders. SP-immunoreactive astrocytes 
h~ve been localized to multiple sclerosis plaques and may 
exacerbate immune-mediated oligodendrocytes destruction 
through the local release of cytokines [6]. IL-6 has been loca- 
1Led to senile plaques in the brain of Alzheimer's disease 
(AD) patients and accumulating evidence suggests that this 
c:, tokine may mediate neurodegeneration by potentiating a 
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Fig. 2. Potentiation by SP of IL-1lS-induced IL-6 secretion in 
I_ 373MG cells. Cells were treated with increasing amounts of IL-l[3 
o: costimulated with the indicated concentrations of [L-II3 and 
0 l~tM SP in the presence or absence of 1 IXM SR 140333. Results 
a~e expressed as net cytokine release after substraction of basal evel 
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Fig. 3. Effects of different selective neurokinin-receptor agonists or 
antagonists on IL-6 production. U373MG cells were treated with 
various concentrations of the following agonists (A): SP (NK1), 
NKA (NK2) and NKB (NK3), or cotreated with 10 nM SP and 
the following antagonists (B): SR140333 (NK1), SR 48968 (NK2) 
and SR 142801 (NK3) (basal evel = 430_ 45 pg/ml). 
local acute-phase response [17-19] including the production 
of amyloid precursor protein (APP) and protease inhibitors 
such as cq-antichymotrypsin a d ~2-macroglobulin. These 
two potent inhibitors prevent normal APP processing and 
favor the pathological degradation of APP into [3-amyloid 
plaques [17,19]. IL-6 has also been shown to induce nerve 
growth factor (NGF) which potentiates the neurotoxicity of 
13-amyloid peptides and contribute to neuritic plaques [20,21]. 
IL-I[5, which has also been found in AD brains, is another 
cytokine which could play a major role in neurodegeneration 
by inducing astrocytosis and stimulating IL-6 release from 
astrocytes [22]. In this respect, the observation made in this 
study that SP induced additional IL-6 release in IL-l[3-stimu- 
lated astrocytes i of particular importance. Thus, SP as in- 
trinsic inducer or enhancing agent of inflammatory cytokines 
involved in neurodegenerative diseases may participate in the 
pathological process of such disorders. With regard to the 
understanding of the pathophysiological responses specifically 
induced or enhanced by SP in the brain, the availability of 
potent SP antagonists such as SR 140333 can be of major 
interest. 
In addition to its well-documented ffect on inflammatory 
cytokine release by cells of the CNS, SP has also been re- 
ported to stimulate at the periphery the production of these 
mediators by human blood monocytes or mononuclear cells 
[11 13]. We therefore sought to evaluate the potency of our 
compound SR 140333 on these SP-stimulated peripheral tar- 
get cells. Surprisingly, in our hands, no effect of SP, alone or 
associated with suboptimal concentrations of LPS, was ob- 
served on IL-1, IL-6 and TNF~ production from human per- 
324 
ipheral blood cells of different donors. Under similar condi- 
tions, using purified monocytes instead of total mononuclear 
cells, and measuring IL-I[3 secretion as a marker of inflam- 
matory response upon SP stimulation, we noted the same 
absence of effect of the neuropeptide (not shown). These re- 
sults are in contrast to the reports mentioned above indicating 
that SP, at nanomolar concentrations, can directly stimulate 
cytokines uch as IL-1, TNFc~ and IL-6 in peripheral blood 
monocytes [11,12] or mononuclear cells [13]. Our data are 
rather in agreement with the fact that no NK1 receptor has 
been detected on human peripheral monocytes or B-cells 
[23,24]. Recently, Jeurissen et al. [24], using membrane prep- 
arations from human monocytes, have found a 'non-classi- 
cal' SP receptor which binds SP with an apparent affinity of 
224 nM which is almost 800-fold lower than the binding affin- 
ity of SP reported on the U373MG astrocytes (Kd --- 0.29 nM) 
[16]. The same group showed at a functional level that the 
stimulation by SP of this non-classical receptor on human 
monocytes leads to the secretion of IL-6 only at 30 and 100 
~tM SP [25]. These high micromolar concentrations do not 
correlate the apparent affinity of SP for this 'atypical' recep- 
tor. Such high concentrations of SP are more in accordance 
with the Kd for non-specific binding of SP to lipid bilayers of 
the membranes (2.7-220 p.M) [26]. This non-specific and re- 
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Fig. 4. Absence of effect of SP on the secretion of IL-113, IL-6 and 
TNFc~ by human peripheral blood mononuclear cells. Human 
PBMNC were cultured with the indicated concentrations of SP. 
LPS as positive control was used at 100 ng/ml. 







500 I i I I I 
0.01 0.1 1 10 100 
LPS (ng/mi) 
Fig. 5. Effect of the association SP and LPS on IL-6 release by hu- 
man PBMNC. Cells were treated with the indicated concentrations 
of LPS alone or associated with 1 ~M SP (basal level = 525 + 55 pg/ 
ml). 
directly G-proteins in the cytosolic compartment [27] and 
has been proposed to be the basis for the SP-induced his- 
tamine release in mast cells [28] and the intracellular rise of 
Ca 2+ in T-lymphocytes [29]. All these reports demonstrate 
that several evels of discrepancies xist about both the type 
of SP binding structure on monocytes and the range of SP 
concentrations required to stimulate them. Although our data 
do not negate or support he existence for a classical or an 
atypical SP-receptor, we clearly and repetitively demonstrated 
that SP at physiologically relevant concentrations was unable 
to stimulate the secretion of inflammatory cytokines by per- 
ipheral ymphoid cells. 
In contrast o its absence of effect on these peripheral tar- 
gets, SP has been confirmed in this study, in a cellular model 
representative of astrocytes of the central nervous ystem, as a 
very effective inducing or potentiating agent of this type of 
mediators. Functional SP receptors have been identified in 
mouse and rat primary astrocytes [30,31] and enhanced secre- 
tion of inflammatory cytokines has been demonstrated upon 
SP stimulation of these cells [32,33]. This indicates that the 
pro-inflammatory effect of SP observed on astrocytoma cell 
lines can be extended to normal primary astrocytes. With 
regard to the possible deleterious effect of SP-stimulated in- 
flammatory mediators in certain brain diseases, drugs such as 
SR 140333 that interfere with SP-driven neurological re- 
sponses may represent a new therapeutic approach to cyto- 
kine-mediated neuropathologies. This may have particular re- 
levance to Alzheimer's disease as amyloid plaques are found 
in the highest density in the olfactory system [34], an area of 
the brain also richly innervated by SP-containing neurons 
[35,36] and where local overproduction f inflammatory c to- 
kines by glial cells could mediate acute phase protein produc- 
tion and amyloidogenesis [19]. 
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